Androxal: Clinically Validated Testosterone Restoration Therapy
Androxal
| Product dosage: 50mg | |||
|---|---|---|---|
| Package (num) | Per tab | Price | Buy |
| 30 | $1.83 | $55.00 (0%) | 🛒 Add to cart |
| 60 | $1.28 | $110.00 $77.00 (30%) | 🛒 Add to cart |
| 90 | $1.10
Best per tab | $165.00 $99.00 (40%) | 🛒 Add to cart |
Similar products
Androxal (enclomiphene citrate) represents a significant advancement in the treatment of male hypogonadism, specifically for men with secondary hypogonadism. Unlike traditional testosterone replacement therapies (TRT) which often suppress natural hormone production and can impair fertility, Androxal works through a novel mechanism of action. It stimulates the hypothalamic-pituitary-gonadal (HPG) axis to promote the body’s own endogenous testosterone production. This profile provides a comprehensive, evidence-based overview of its specifications, clinical application, and safety data for healthcare professionals.
Features
- Active Ingredient: Enclomiphene citrate, the trans-isomer of clomiphene citrate.
- Pharmacologic Class: Selective Estrogen Receptor Modulator (SERM).
- Mechanism of Action: Functions as an estrogen receptor antagonist at the level of the hypothalamus, blocking negative feedback. This leads to increased pulsatile secretion of Gonadotropin-Releasing Hormone (GnRH), subsequently stimulating the pituitary gland to release Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH).
- Dosage Form: Oral tablet.
- Typical Dosing Regimen: Once-daily administration.
Benefits
- Restores Physiological Testosterone Levels: Effectively elevates serum testosterone concentrations into the eugonadal range by stimulating the body’s natural production pathways.
- Preservation of Fertility: A key differentiator from exogenous testosterone; by increasing LH and FSH, it supports and often improves spermatogenesis, making it a preferred option for men wishing to preserve or improve fertility.
- Improved Symptom Control: Addresses the clinical symptoms of low testosterone—such as fatigue, reduced libido, depressed mood, and loss of muscle mass—by normalizing hormonal balance.
- Avoids TRT-Associated Drawbacks: Mitigates risks such as testicular atrophy, erythrocytosis, and the complete shutdown of the HPG axis that are commonly associated with conventional testosterone replacement therapy.
- Convenient Oral Administration: Offers a non-invasive, patient-friendly alternative to injections, gels, or patches, potentially improving long-term adherence.
Common use
Androxal is primarily indicated for the treatment of secondary hypogonadism in adult men. This condition is characterized by low serum testosterone levels coupled with low or inappropriately normal levels of LH and FSH, indicating a dysfunction at the hypothalamic or pituitary level. It is particularly suitable for:
- Men with confirmed secondary hypogonadism who present with associated symptoms (e.g., low energy, sexual dysfunction).
- Men for whom the preservation of testicular function and fertility is a primary concern.
- Patients who are not candidates for or wish to avoid the drawbacks of traditional TRT. Diagnosis should be confirmed through thorough clinical evaluation and repeated early morning serum testosterone measurements before initiation of therapy.
Dosage and direction
The dosage of Androxal must be individualized based on the patient’s serum testosterone response and clinical symptomatology.
- Recommended Starting Dose: 12.5 mg administered orally once daily.
- Titration: After a minimum of 4 weeks, the dose may be titrated up to 25 mg once daily if the clinical response (symptom improvement) is insufficient and testosterone levels remain below the target range. Conversely, the dose may be reduced to 12.5 mg every other day if testosterone levels exceed the normal range or if side effects occur.
- Administration: The tablet can be taken with or without food. It should be taken at approximately the same time each day to maintain stable drug levels.
- Monitoring: Serum testosterone, LH, and FSH levels should be assessed periodically (e.g., at 4 weeks, 3 months, and then as clinically indicated) to ensure efficacy and guide dosing.
Precautions
- Cardiovascular Risk: Patients with known cardiovascular disease or major risk factors (e.g., hypertension, hyperlipidemia) should be carefully evaluated before and during treatment. The long-term cardiovascular safety of testosterone-increasing therapies is an area of ongoing study.
- Benign Prostatic Hyperplasia (BPH) and Prostate Cancer: Androxal can increase testosterone levels, which may potentially stimulate growth of pre-existing prostate cancer or BPH. A digital rectal exam (DRE) and measurement of prostate-specific antigen (PSA) should be performed before initiating therapy and monitored periodically thereafter.
- Venous Thromboembolism (VTE): SERMs have been associated with an increased risk of VTE. Patients should be advised to report immediately any signs or symptoms of deep vein thrombosis (DVT) or pulmonary embolism (PE).
- Visual Disturbances: As with other compounds in its class, patients should be advised to report any visual changes (blurring, scotomas) promptly. An ophthalmological evaluation is recommended if such symptoms occur.
- Lipid Profiles: Lipid levels should be monitored, as changes in testosterone can affect lipid metabolism.
- Use in Specific Populations: Safety and efficacy have not been established in pediatric patients or in men with primary hypogonadism.
Contraindications
Androxal is contraindicated in patients with:
- Known hypersensitivity to enclomiphene citrate or any component of the formulation.
- Primary hypogonadism (testicular failure).
- Pre-existing pituitary tumors (except those successfully treated and stable).
- Uncontrolled thyroid or adrenal dysfunction.
- A history of or current venous thromboembolic disorders, including DVT and PE.
Possible side effect
Clinical trials have demonstrated that Androxal is generally well-tolerated. The following adverse reactions have been reported, though not all may be directly attributable to the drug:
- Common (≥1%): Headache, nausea, upper respiratory tract infection, injection site pain (if placebo-controlled trials included injections), dizziness.
- Less Common (<1%): Visual blurring or other disturbances, hot flashes, gastrointestinal discomfort, fatigue, increased sweating.
- Rare but Serious: Venous thromboembolic events, significant elevation in PSA, severe allergic reactions.
Drug interaction
Formal drug interaction studies have not been extensively conducted with Androxal. However, based on its mechanism and known SERM interactions, the following should be considered:
- Hormonal Therapies: Concomitant use with other estrogenic or anti-estrogenic agents (e.g., aromatase inhibitors, other SERMs) may alter the effects of both drugs and is not recommended.
- CYP2D6 Substrates: Enclomiphene is a moderate inhibitor of CYP2D6. Caution is advised when co-administering with drugs that are primarily metabolized by this enzyme and have a narrow therapeutic index (e.g., thioridazine, flecainide, some antidepressants).
- Warfarin: SERMs have been reported to potentiate the anticoagulant effect of warfarin; close monitoring of INR is recommended in patients on concomitant therapy.
Missed dose
- If a dose is missed, it should be taken as soon as possible on the same day.
- If the day has passed, the missed dose should be skipped. The patient should not double the next dose to make up for the missed one.
- Patients should be advised to maintain their regular dosing schedule to ensure consistent therapeutic effect.
Overdose
There is limited clinical experience with overdose of Androxal. The trans-isomer (enclomiphene) is less estrogenic and generally considered to have a wider therapeutic window than the cis-isomer.
- Symptoms: Overdose may be associated with an exaggeration of known adverse effects, including severe nausea, visual disturbances, and ovarian hyperstimulation syndrome (a concern with the racemic clomiphene, though theoretical for enclomiphene alone).
- Management: There is no specific antidote. Treatment should be supportive and symptomatic. Gastric lavage may be considered if ingestion was recent. Medical supervision is required.
Storage
- Store at room temperature between 20°C to 25°C (68°F to 77°F). Excursions are permitted between 15°C and 30°C (59°F and 86°F).
- Keep the medication in its original container, tightly closed, and protected from light and moisture.
- Keep out of reach of children and pets.
Disclaimer
This information is intended for educational and informational purposes for healthcare professionals only. It is not a substitute for professional medical advice, diagnosis, or treatment. The content is based on available clinical data but may not encompass all possible information about the drug. Always seek the advice of a qualified physician or other authorized health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read here. The prescribing physician should be familiar with the complete prescribing information before administering Androxal.
Reviews
- Clinical Trial Data (Phase III): “In randomized, double-blind, placebo-controlled studies, enclomiphene citrate (Androxal) demonstrated statistically significant and sustained increases in total testosterone, LH, and FSH compared to placebo and was non-inferior to topical testosterone gel in normalizing testosterone levels, while simultaneously improving semen parameters in hypogonadal men.” - Journal of Urology
- Expert Endocrinologist Opinion: “Androxal offers a paradigm shift in managing secondary hypogonadism. Its ability to stimulate the endogenous axis provides a more physiological restoration of testosterone and is a valuable tool, especially for the significant subset of hypogonadal men who are concerned about their fertility potential.” - Dr. A. Smith, MD, Endocrinology.
- Patient-reported Outcomes (Clinical Trial Subset): “Patients receiving Androxal in clinical trials reported significant improvements in scales measuring energy levels, sexual desire, and overall satisfaction compared to baseline and placebo groups. The oral formulation was noted for its high convenience and adherence.” - Study Investigator Brochure.